A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir-Reference-Cited by-同舟云学术

A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir

Published:2017-11 Issue: Volume:86 Page:217-225
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

de Weger Vincent A.^ORCID,Stuurman Frederik E.^ORCID,Hendrikx Jeroen J.M.A.,Moes Johannes J.,Sawicki Emilia,Huitema Alwin D.R.,Nuijen Bastiaan,Thijssen Bas,Rosing Hilde,Keessen Marianne,Mergui-Roelvink Marja,Beijnen Jos H.,Schellens Jan H.M.,Marchetti Serena

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Summary of product characteristics (Taxotere);Sanofi-Aventis,2015

2. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel;Hendrikx;Int J cancer,2013

3. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001);Moes;Int J Pharm,2011

4. Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel;Sawicki;Int J Pharm,2016

5. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel;Malingré;J Clin Oncol,2001

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity;Cancer Chemotherapy and Pharmacology;2024-05-11

2. A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer;European Journal of Cancer;2024-05

3. Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment;Cancer Chemotherapy and Pharmacology;2024-03-08

4. Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam;The Journal of Clinical Pharmacology;2023-10-26

5. Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumors;Anti-Cancer Drugs;2022-11-18